Autologous Stem Cell & Non-stem Cell Therapies Market by Type (CAR-T, Tumor Infiltrating Lymphocyte), Indication (Cancer, Musculoskeletal, Dermatology), Source (T-Cells, Mesenchymal Stem Cell), End User (Hospital) - Global Forecast to 2029
The autologous stem cell & non-stem cell therapies market is projected to reach USD 22.2 billion by 2029 from USD 5.5 billion in 2024, at a CAGR of 32.3% during the forecast period. The growth of this market is driven by several factors such as the growing regulatory approvals for autologous CAR T cell-based therapies, increasing R&D investments for the development of autologous cell therapies, and an increase in the demand for personalized medicines.
“The autologous stem cell & non-stem cell therapies market growth for Autologous non-stem cell therapies can be attributed to the increasing number of cancer cases leading to increased demand for substantial treatment option.”
The autologous stem cell & non-stem cell therapies market, based on type segment is further segmented into autologous stem cell therapies and autologous non-stem cell therapies. The autologous non-stem cell therapies sub-segment is further divided into CAR T cell therapies, Tumor Infiltrating Lymphocyte (TIL), and other therapies (of skin grafts, others). The autologous non-stem cell therapies hold the dominant share due to the rise in global cancer cases accelerating the demand for the development of effective cancer treatment solutions such as autologous non-stem-cell-based therapies, which are increasingly valued in the market due to the rising number of regulatory approvals for these therapies and growing number of cancer patients seeking viable treatment alternatives.
“By Indications, the cancer indication subsegment accounted for the largest share of the autologous stem cell & non-stem cell therapies market in 2023.”
The indication segment is further segmented into cancer indications and non-cancer indications. In 2023, the cancer indications subsegment accounted for the largest share of the indication segment due to the rising number of global cancer cases, and a growing demand for the development of effective and efficient cancer therapeutics such as autologous CAR T cell therapies, that are shown to be effective for treating various forms of cancer such as multiple myeloma and various types of lymphoma.
“North American region is expected to register the highest CAGR in the autologous stem cell & non-stem cell therapies market.”
The market for autologous stem cell & non-stem cell therapies in North America is estimated to grow at the highest rate during the forecast period. The rising academic and organizational interest in autologous stem cell and non-stem cell-based research, complemented by the North American healthcare sector's expansion and the rising approvals and utilization of autologous stem cell and non-stem cell-based therapies for cancer and other chronic diseases are factors that will aid the market growth in North America. North America also has an established pharmaceutical manufacturing infrastructure and the presence of prominent players in the autologous stem cell & non-stem cell therapies market such as Gilead Sciences, Inc. (US), Bristol-Myers Squibb Company (US), Johnson & Johnson (US) among others which further supports the leadership position of this region.
The primary interviews conducted for this report can be categorized as follows:
Research Coverage:
This report provides a detailed picture of the autologous stem cell & non-stem cell therapies market. It aims to estimate the market’s size and future growth potential across different segments such as the type, indication, source, end user, and region. The report also includes an in-depth competitive analysis of the key market players and their company profiles, recent developments, key market strategies, funding activities, brand/product comparative analysis, and vendor valuation and financial metrics of the autologous stem cell & non-stem cell therapies market.
Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall autologous stem cell & non-stem cell therapies market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market’s pulse and provide information on the key market drivers, restraints, challenges, trends, and opportunities.
The report provides insights on the following pointers:
“The autologous stem cell & non-stem cell therapies market growth for Autologous non-stem cell therapies can be attributed to the increasing number of cancer cases leading to increased demand for substantial treatment option.”
The autologous stem cell & non-stem cell therapies market, based on type segment is further segmented into autologous stem cell therapies and autologous non-stem cell therapies. The autologous non-stem cell therapies sub-segment is further divided into CAR T cell therapies, Tumor Infiltrating Lymphocyte (TIL), and other therapies (of skin grafts, others). The autologous non-stem cell therapies hold the dominant share due to the rise in global cancer cases accelerating the demand for the development of effective cancer treatment solutions such as autologous non-stem-cell-based therapies, which are increasingly valued in the market due to the rising number of regulatory approvals for these therapies and growing number of cancer patients seeking viable treatment alternatives.
“By Indications, the cancer indication subsegment accounted for the largest share of the autologous stem cell & non-stem cell therapies market in 2023.”
The indication segment is further segmented into cancer indications and non-cancer indications. In 2023, the cancer indications subsegment accounted for the largest share of the indication segment due to the rising number of global cancer cases, and a growing demand for the development of effective and efficient cancer therapeutics such as autologous CAR T cell therapies, that are shown to be effective for treating various forms of cancer such as multiple myeloma and various types of lymphoma.
“North American region is expected to register the highest CAGR in the autologous stem cell & non-stem cell therapies market.”
The market for autologous stem cell & non-stem cell therapies in North America is estimated to grow at the highest rate during the forecast period. The rising academic and organizational interest in autologous stem cell and non-stem cell-based research, complemented by the North American healthcare sector's expansion and the rising approvals and utilization of autologous stem cell and non-stem cell-based therapies for cancer and other chronic diseases are factors that will aid the market growth in North America. North America also has an established pharmaceutical manufacturing infrastructure and the presence of prominent players in the autologous stem cell & non-stem cell therapies market such as Gilead Sciences, Inc. (US), Bristol-Myers Squibb Company (US), Johnson & Johnson (US) among others which further supports the leadership position of this region.
The primary interviews conducted for this report can be categorized as follows:
- By Respondent: Supply Side- 70% and Demand Side - 30%
- By Designation: C Level Executives- 55%, CXOs, and Director level - 20%, and Others- 25%
- By Region: North America -50%, Europe - 20%, Asia-Pacific -20%, RoW -10%
- Gilead Sciences, Inc. (US)
- Bristol-Myers Squibb Company (US)
- Johnson & Johnson (US)
- Vericel Corporation (US)
- Novartis AG (Switzerland)
- JW (Cayman) Therapeutics Co. Ltd (China)
- APAC Biotech (India)
- Regrow Biosciences Pvt Ltd. (India)
- Healiva SA (Switzerland)
Research Coverage:
This report provides a detailed picture of the autologous stem cell & non-stem cell therapies market. It aims to estimate the market’s size and future growth potential across different segments such as the type, indication, source, end user, and region. The report also includes an in-depth competitive analysis of the key market players and their company profiles, recent developments, key market strategies, funding activities, brand/product comparative analysis, and vendor valuation and financial metrics of the autologous stem cell & non-stem cell therapies market.
Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall autologous stem cell & non-stem cell therapies market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market’s pulse and provide information on the key market drivers, restraints, challenges, trends, and opportunities.
The report provides insights on the following pointers:
- Analysis of key drivers (e.g., increasing government approvals for various autologous cell-based therapies, increasing investments and funding towards the development of autologous cell-based therapies and the growing number of clinical trials involving autologous stem and non-stem cells), restraints (e.g., uptake of allogeneic cell-based therapies as substitutes), opportunities (e.g, outsourcing manufacturing of cell therapy and focus on closed automated systems), and challenges (e.g, regulatory complications and reimbursement challenges and issues in scalable manufacturing) are influencing the growth of the autologous stem cell & non-stem cell therapies market.
- Product Approvals: Detailed insights on newly approved products of the autologous stem cell & non-stem cell therapies market.
- Market Development: Comprehensive information about lucrative markets – the report analyses the autologous stem cell & non-stem cell therapies market across varied regions.
- Market Diversification: Exhaustive information about new products, recent developments, and investments in the autologous stem cell & non-stem cell therapies market.
- Pipeline Analysis: Comprehensive information about products under clinical trials.
- Competitive Assessment: In-depth assessment of market shares, growth strategies, and product offerings of leading players including Gilead Sciences, Inc. (US), Bristol-Myers Squibb Company (US), Johnson & Johnson (US), Vericel Corporation (US), Novartis AG (Switzerland), JW (Cayman) Therapeutics Co. Ltd (China), Iovance Biotherapeutics, Inc. (US), APAC Biotech (India), Regrow Biosciences Pvt Ltd. (India), healiva SA (Switzerland), Green Cross Holdings Co., Ltd. (GC Cell) (Republic of Korea)), Sanpower Group Co., Ltd. (Dendreon Pharmaceuticals Llc. (China), Tegoscience (South Korea), ImmunoACT (India), CARsgen Therapeutics Holdings Limited (China), IASO Biotherapeutics (China), Pharmicell Co., Ltd (South Korea), Anterogen.Co.,Ltd. (South Korea) among others offering autologous stem cell & non-stem cell-based therapeutic products.
1 INTRODUCTION
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS & EXCLUSIONS
1.3 MARKET SCOPE
1.3.1 MARKET SEGMENTATION
1.3.2 REGIONAL SEGMENTATION
FIGURE 1 REGIONS COVERED
1.3.3 YEARS CONSIDERED
1.3.4 CURRENCY CONSIDERED
1.4 STAKEHOLDERS
1.5 SUMMARY OF CHANGES
1.6 RECESSION IMPACT
2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
FIGURE 2 RESEARCH DESIGN
2.1.1 SECONDARY DATA
2.1.2 PRIMARY DATA
FIGURE 3 BREAKDOWN OF PRIMARIES: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS
2.2 MARKET SIZE ESTIMATION
FIGURE 4 AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET: MARKET SIZE ESTIMATION FOR SUPPLY-SIDE ANALYSIS, 2023
FIGURE 5 AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET: REVENUE SHARE ANALYSIS, 2023
FIGURE 6 GILEAD SCIENCES, INC.: REVENUE SHARE ANALYSIS, 2023
2.3 PRIMARY INSIGHTS
FIGURE 7 VALIDATION FROM PRIMARY EXPERTS
2.3.1 SEGMENTAL ASSESSMENT
FIGURE 8 MARKET SIZE ESTIMATION: TOP-DOWN APPROACH
2.4 GROWTH FORECAST
FIGURE 9 AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET: CAGR PROJECTIONS (2024–2029)
FIGURE 10 GROWTH ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
2.5 VOLUME ESTIMATION
2.6 MARKET BREAKDOWN & DATA TRIANGULATION
FIGURE 11 DATA TRIANGULATION METHODOLOGY
2.7 STUDY ASSUMPTIONS
2.8 RISK ANALYSIS
TABLE 1 AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET: RISK ASSESSMENT ANALYSIS
2.9 RECESSION IMPACT ANALYSIS
TABLE 2 GLOBAL INFLATION RATE PROJECTIONS, 2021–2028 (% GROWTH)
3 EXECUTIVE SUMMARY
FIGURE 12 AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY TYPE, 2024 VS. 2029 (USD MILLION)
FIGURE 13 AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY INDICATION, 2024 VS. 2029 (USD MILLION)
FIGURE 14 AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY SOURCE, 2024 VS. 2029 (USD MILLION)
FIGURE 15 AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY END USER, 2024?2029
FIGURE 16 GEOGRAPHICAL SNAPSHOT OF AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET
4 PREMIUM INSIGHTS
4.1 AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET OVERVIEW
FIGURE 17 RISING REGULATORY APPROVALS FOR CAR T-CELL THERAPIES TO DRIVE MARKET
4.2 NORTH AMERICA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY TYPE AND COUNTRY (2023)
FIGURE 18 AUTOLOGOUS NON-STEM CELL THERAPIES SEGMENT ACCOUNTED FOR LARGEST MARKET SHARE IN 2023
4.3 AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SHARE, BY SOURCE, 2024 VS. 2029
FIGURE 19 T-CELLS SOURCE SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD
4.4 AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SHARE, BY INDICATION, 2023
FIGURE 20 CANCER INDICATION SEGMENT TO ACCOUNT FOR LARGEST MARKET SHARE IN 2023
4.5 AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
FIGURE 21 ASIA PACIFIC REGION TO GROW AT HIGHEST CAGR DURING FORECAST PERIOD
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
FIGURE 22 AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
TABLE 3 AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET: IMPACT ANALYSIS
5.2.1 DRIVERS
5.2.1.1 Rising approvals for CAR T-cell therapies
TABLE 4 APPROVED AUTOLOGOUS CAR T-CELL THERAPIES
5.2.1.2 Increasing R&D investments in autologous therapeutics
5.2.1.3 Increasing demand for personalized medicine
5.2.2 RESTRAINTS
5.2.2.1 Uptake of allogeneic cell-based therapies as substitutes
5.2.3 OPPORTUNITIES
5.2.3.1 Rising outsourcing of manufacturing activities
5.2.3.2 Adoption of closed automated systems
5.2.4 CHALLENGES
5.2.4.1 Stringent regulatory guidelines and reimbursement challenges
5.2.4.2 Issues associated with scalable manufacturing
5.3 SUPPLY CHAIN ANALYSIS
FIGURE 23 SUPPLY CHAIN ANALYSIS: DIRECT DISTRIBUTION STRATEGY PREFERRED BY PROMINENT COMPANIES
5.4 TECHNOLOGY ANALYSIS
5.4.1 KEY TECHNOLOGIES
5.4.1.1 Genome editing
5.4.1.2 Synthetic biology
5.4.2 COMPLEMENTARY TECHNOLOGIES
5.4.2.1 Process analytical technology (PAT)
5.4.2.2 Point-of-care manufacturing
5.5 VALUE CHAIN ANALYSIS
FIGURE 24 VALUE CHAIN ANALYSIS—MAXIMUM VALUE IS ADDED DURING THERAPY MANUFACTURING PHASE
5.6 PRICING ANALYSIS
TABLE 5 AVERAGE SELLING PRICE FOR LEADING AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPEUTIC DRUGS
TABLE 6 AVERAGE SELLING PRICE FOR MAJOR AUTOLOGOUS STEM CELL AND NON-STEM CELL BASED THERAPEUTIC DRUGS, BY REGION
5.7 ECOSYSTEM ANALYSIS
5.7.1 ROLE IN ECOSYSTEM
5.8 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
FIGURE 26 REVENUE SHIFT AND NEW REVENUE POCKETS FOR AUTOLOGOUS STEM CELL AND NON-STEM CELL THERAPY MARKET MANUFACTURERS
5.9 PATENT ANALYSIS
5.9.1 PATENT ANALYSIS: AUTOLOGOUS CAR-T THERAPIES
FIGURE 27 PATENT APPLICATIONS FOR AUTOLOGOUS CAR-T THERAPIES, JANUARY 2013–OCTOBER 2023
5.9.2 PATENT ANALYSIS: TIL THERAPY
FIGURE 28 PATENT APPLICATIONS FOR TIL THERAPIES, JANUARY 2013–OCTOBER 2023
5.10 KEY CONFERENCES & EVENTS, 2024?2025
TABLE 7 AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET: LIST OF CONFERENCES & EVENTS
5.11 REGULATORY LANDSCAPE
5.11.1 REGULATORY ANALYSIS
5.11.2 NORTH AMERICA
5.11.2.1 US
5.11.2.2 Canada
5.11.3 EUROPE
5.11.3.1 Germany
5.11.3.2 UK
5.11.3.3 Rest of Europe
5.11.4 ASIA PACIFIC
5.11.4.1 China
5.11.4.2 Japan
5.11.4.3 South Korea
5.11.4.4 Australia
5.11.4.5 Rest of Asia Pacific
5.11.5 REGULATORY BODIES AND ORGANIZATIONS
TABLE 8 NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 9 EUROPE: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 10 ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 11 LATIN AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 12 MIDDLE EAST & AFRICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.12 PORTER’S FIVE FORCES ANALYSIS
FIGURE 29 AUTOLOGOUS STEM CELL & NON-STEM CELL MARKET: PORTER'S FIVE FORCE ANALYSIS
TABLE 13 PORTER’S FIVE FORCES ANALYSIS
5.12.1 DEGREE OF COMPETITION
5.12.2 BARGAINING POWER OF SUPPLIERS
5.12.3 BARGAINING POWER OF BUYERS
5.12.4 THREAT OF SUBSTITUTES
5.12.5 THREAT OF NEW ENTRANTS
5.13 KEY STAKEHOLDERS & BUYING CRITERIA
FIGURE 30 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY END USER
5.14 KEY BUYING CRITERIA
5.14.1 BUYING CRITERIA OF END USERS FOR AUTOLOGOUS STEM CELL AND NON-STEM CELL THERAPEUTIC PRODUCTS
5.14.2 BUYING CRITERIA FOR AUTOLOGOUS STEM CELL AND NON-STEM CELL THERAPEUTIC PRODUCTS, BY END USER
5.15 INVESTMENT AND FUNDING SCENARIO
5.16 CASE STUDY ANALYSIS
5.16.1 CASE STUDY 1
5.16.1.1 Comparative Analysis of Cupistem Efficacy in Treatment of Crohn's Perianal Fistulas
5.16.2 CASE STUDY 2
5.16.2.1 Evaluating Lenzumestrocel (Neuronata-R) in Amyotrophic Lateral Sclerosis: The ALSUMMIT Phase III Trial Protocol
5.16.3 CASE STUDY 3
5.16.3.1 Stemirac Stem Cell Therapy for Traumatic Spinal Cord Injury
5.16.4 CASE STUDY 4
5.16.4.1 Efficacy and Safety of Holoclar in Limbal Stem Cell Deficiency
6 AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY TYPE
6.1 INTRODUCTION
TABLE 14 AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 15 AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY TYPE, 2022–2029 (UNITS)
6.2 AUTOLOGOUS STEM CELL THERAPIES
6.2.1 RISING INCIDENCE OF CHRONIC DISEASES TO DRIVE MARKET
TABLE 16 AUTOLOGOUS STEM CELL THERAPIES MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 17 NORTH AMERICA: AUTOLOGOUS STEM CELL THERAPIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 18 EUROPE: AUTOLOGOUS STEM CELL THERAPIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 19 ASIA PACIFIC: AUTOLOGOUS STEM CELL MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 20 LATIN AMERICA: AUTOLOGOUS STEM CELL THERAPIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 21 MIDDLE EAST: AUTOLOGOUS STEM CELL MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 22 GCC COUNTRIES: AUTOLOGOUS STEM CELL MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
6.3 AUTOLOGOUS NON-STEM CELL THERAPIES
TABLE 23 AUTOLOGOUS NON-STEM CELL THERAPIES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 24 AUTOLOGOUS NON-STEM CELL THERAPIES MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 25 NORTH AMERICA: AUTOLOGOUS NON-STEM CELL THERAPIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 26 EUROPE: AUTOLOGOUS NON-STEM CELL THERAPIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 27 ASIA PACIFIC: AUTOLOGOUS NON-STEM CELL THERAPIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
6.4 CAR T-CELL THERAPIES
6.4.1 GROWING APPROVAL OF AUTOLOGOUS CAR T-CELL THERAPIES TO BOOST GROWTH
TABLE 28 CAR T-CELL THERAPIES MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 29 NORTH AMERICA: CAR T-CELL THERAPIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 30 EUROPE: CAR T-CELL THERAPIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 31 ASIA PACIFIC: CAR T-CELL THERAPIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
6.5 TUMOR-INFILTRATING LYMPHOCYTES (TILS)
6.5.1 EMERGING POTENTIAL OF TIL IN CANCER TREATMENT TO BOOST DEMAND
TABLE 32 TUMOR-INFILTRATING LYMPHOCYTES MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 33 NORTH AMERICA: TUMOR-INFILTRATING LYMPHOCYTES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
7 AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY INDICATION
7.1 INTRODUCTION
TABLE 34 AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY INDICATION, 2022–2029 (USD MILLION)
7.2 CANCER INDICATION
7.2.1 RISING INCIDENCE OF CANCER AND GROWING DEMAND FOR THERAPEUTICS TO DRIVE MARKET
TABLE 35 AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKEY FOR CANCER INDICATIONS, BY REGION, 2022–2029 (USD MILLION)
TABLE 36 NORTH AMERICA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR CANCER INDICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 37 EUROPE: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR CANCER INDICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 38 ASIA PACIFIC: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR CANCER INDICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
7.3 MUSCULOSKELETAL INDICATION
7.3.1 GROWING INCIDENCE OF OSTEOARTHRITIS TO DRIVE MARKET
TABLE 39 AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR MUSCULOSKELETAL INDICATIONS, BY REGION, 2022–2029 (USD MILLION)
TABLE 40 NORTH AMERICA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR MUSCULOSKELETAL INDICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 41 EUROPE: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR MUSCULOSKELETAL INDICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 42 ASIA PACIFIC: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR MUSCULOSKELETAL INDICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 43 LATIN AMERICA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR MUSCULOSKELETAL INDICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 44 MIDDLE EAST: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR MUSCULOSKELETAL INDICATIONS, BY REGION, 2022–2029 (USD MILLION)
TABLE 45 GCC COUNTRIES: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR MUSCULOSKELETAL INDICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
7.4 DERMATOLOGY INDICATION
7.4.1 INCREASING PREVALENCE OF SKIN DISORDERS TO SUPPORT MARKET GROWTH
TABLE 46 AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR DERMATOLOGICAL INDICATIONS, BY REGION, 2022–2029 (USD MILLION)
TABLE 47 NORTH AMERICA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR DERMATOLOGICAL INDICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 48 EUROPE: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR DERMATOLOGICAL INDICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 49 ASIA PACIFIC: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR DERMATOLOGICAL INDICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 50 LATIN AMERICA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR DERMATOLOGICAL INDICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 51 MIDDLE EAST: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR DERMATOLOGICAL INDICATIONS, BY REGION, 2022–2029 (USD MILLION)
TABLE 52 GCC COUNTRIES: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR DERMATOLOGICAL INDICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
7.5 OTHER INDICATIONS
TABLE 53 AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR OTHER INDICATIONS, BY REGION, 2022–2029 (USD MILLION)
TABLE 54 NORTH AMERICA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 55 EUROPE: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 56 ASIA PACIFIC: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 57 LATIN AMERICA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 58 MIDDLE EAST: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR OTHER INDICATIONS, BY REGION, 2022–2029 (USD MILLION)
TABLE 59 GCC COUNTRIES: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
8 AUTOLOGOUS STEM CELL AND NON-STEM CELL THERAPIES MARKET, BY SOURCE
8.1 INTRODUCTION
TABLE 60 AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY SOURCE, 2022–2029 (USD MILLION)
8.2 T-CELLS
8.2.1 GROWING ADOPTION OF CAR T-CELL THERAPIES TO DRIVE MARKET
TABLE 61 AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR T-CELLS, BY REGION, 2022–2029 (USD MILLION)
TABLE 62 NORTH AMERICA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR T-CELLS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 63 EUROPE: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR T-CELLS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 64 ASIA PACIFIC: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR T-CELLS, BY COUNTRY, 2022–2029 (USD MILLION)
8.3 MESENCHYMAL STEM CELLS
8.3.1 HIGH UPTAKE IN DEVELOPMENT OF AUTOLOGOUS THERAPIES TO SUPPORT MARKET GROWTH
TABLE 65 AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR MESENCHYMAL STEM CELLS, BY REGION, 2022–2029 (USD MILLION)
TABLE 66 NORTH AMERICA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR MESENCHYMAL STEM CELLS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 67 EUROPE: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR MESENCHYMAL STEM CELLS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 68 ASIA PACIFIC: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR MESENCHYMAL STEM CELLS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 69 LATIN AMERICA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR MESENCHYMAL STEM CELLS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 70 MIDDLE EAST: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR MESENCHYMAL STEM CELLS, BY REGION, 2022–2029 (USD MILLION)
TABLE 71 GCC COUNTRIES: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR MESENCHYMAL STEM CELLS, BY COUNTRY, 2022–2029 (USD MILLION)
9 AUTOLOGOUS STEM-CELL & NON-STEM CELL THERAPIES MARKET, BY END USER
9.1 INTRODUCTION
TABLE 72 AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY END USER, 2022–2029 (USD MILLION)
9.2 HOSPITALS AND CLINICS
9.2.1 ABILITY TO UNDERTAKE APHERESIS PROCEDURES WITH ADVANCED HEALTHCARE INFRASTRUCTURE TO DRIVE MARKET
TABLE 73 AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR HOSPITALS AND CLINICS, BY REGION, 2022–2029 (USD MILLION)
TABLE 74 NORTH AMERICA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR HOSPITALS AND CLINICS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 75 EUROPE: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR HOSPITALS AND CLINICS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 76 ASIA PACIFIC: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR HOSPITALS AND CLINICS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 77 LATIN AMERICA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR HOSPITALS AND CLINICS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 78 MIDDLE EAST: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR HOSPITALS AND CLINICS, BY REGION, 2022–2029 (USD MILLION)
TABLE 79 GCC COUNTRIES: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR HOSPITALS AND CLINICS, BY COUNTRY, 2022–2029 (USD MILLION)
9.3 LONG-TERM CARE FACILITIES
9.3.1 RISING INCIDENCE OF CHRONIC DISEASES TO SUPPORT MARKET GROWTH
TABLE 80 AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR LONG-TERM CARE FACILITIES, BY REGION, 2022–2029 (USD MILLION)
TABLE 81 NORTH AMERICA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 82 EUROPE: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 83 ASIA PACIFIC: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 84 LATIN AMERICA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 85 MIDDLE EAST: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR LONG-TERM CARE FACILITIES, BY REGION, 2022–2029 (USD MILLION)
TABLE 86 GCC COUNTRIES: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2022–2029 (USD MILLION)
9.4 SPECIALTY CARE CENTERS
9.4.1 GROWING PREFERENCE FOR PERSONALIZED MEDICINE TO BOOST DEMAND
TABLE 87 AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR SPECIALTY CARE CENTERS, BY REGION, 2022–2029 (USD MILLION)
TABLE 88 NORTH AMERICA: AUTOLOGOUS STEM CELL & NON-STEM CELL FOR SPECIALTY CARE CENTERS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 89 EUROPE: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR SPECIALTY CARE CENTERS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 90 ASIA PACIFIC: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR SPECIALTY CARE CENTERS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 91 LATIN AMERICA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR SPECIALTY CARE CENTERS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 92 MIDDLE EAST: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR SPECIALTY CARE CENTERS, BY REGION, 2022–2029 (USD MILLION)
TABLE 93 GCC COUNTRIES: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR SPECIALTY CARE CENTERS, BY COUNTRY, 2022–2029 (USD MILLION)
10 AUTOLOGOUS STEM CELL AND NON-STEM STEM CELL THERAPIES MARKET, BY REGION
10.1 INTRODUCTION
TABLE 94 AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY REGION, 2022–2029 (USD MILLION)
10.2 NORTH AMERICA
10.2.1 NORTH AMERICA: RECESSION IMPACT
FIGURE 31 NORTH AMERICA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SNAPSHOT
TABLE 95 NORTH AMERICA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 96 NORTH AMERICA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 97 NORTH AMERICA: AUTOLOGOUS NON-STEM CELL THERAPIES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 98 NORTH AMERICA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY SOURCE, 2022–2029 (USD MILLION)
TABLE 99 NORTH AMERICA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY INDICATION, 2022–2029 (USD MILLION)
TABLE 100 NORTH AMERICA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY END USER, 2022–2029 (USD MILLION)
10.2.2 US
10.2.2.1 Rising R&D activities for stem cell therapies to drive market
TABLE 101 US: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 102 US: AUTOLOGOUS NON-STEM CELL THERAPIES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 103 US: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY SOURCE, 2022–2029 (USD MILLION)
TABLE 104 US: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY INDICATION, 2022–2029 (USD MILLION)
TABLE 105 US: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY END USER, 2022–2029 (USD MILLION)
10.2.3 CANADA
10.2.3.1 Rising government initiatives for regenerative medicine research to drive market
TABLE 106 CANADA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 107 CANADA: AUTOLOGOUS NON-STEM CELL THERAPIES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 108 CANADA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY SOURCE, 2022–2029 (USD MILLION)
TABLE 109 CANADA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY INDICATION, 2022–2029 (USD MILLION)
TABLE 110 CANADA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY END USER, 2022–2029 (USD MILLION)
10.3 EUROPE
10.3.1 EUROPE: RECESSION IMPACT
TABLE 111 EUROPE: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 112 EUROPE: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 113 EUROPE: AUTOLOGOUS NON-STEM CELL THERAPIES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 114 EUROPE: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY SOURCE, 2022–2029 (USD MILLION)
TABLE 115 EUROPE: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY INDICATION, 2022–2029 (USD MILLION)
TABLE 116 EUROPE: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY END USER, 2022–2029 (USD MILLION)
10.3.2 GERMANY
10.3.2.1 Rising focus on clinical research to drive market
TABLE 117 GERMANY: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 118 GERMANY: AUTOLOGOUS NON-STEM CELL THERAPIES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 119 GERMANY: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY SOURCE, 2022–2029 (USD MILLION)
TABLE 120 GERMANY: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY INDICATION, 2022–2029 (USD MILLION)
TABLE 121 GERMANY: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY END USER, 2022–2029 (USD MILLION)
10.3.3 UK
10.3.3.1 Rising technological advancements in automation to drive market
TABLE 122 UK: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 123 UK: AUTOLOGOUS NON-STEM CELL THERAPIES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 124 UK: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY SOURCE, 2022–2029 (USD MILLION)
TABLE 125 UK: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY INDICATION, 2022–2029 (USD MILLION)
TABLE 126 UK: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY END USER, 2022–2029 (USD MILLION)
10.3.4 FRANCE
10.3.4.1 Growing focus on cell & gene therapy initiatives to boost demand
TABLE 127 FRANCE: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 128 FRANCE: AUTOLOGOUS NON-STEM CELL THERAPIES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 129 FRANCE: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY SOURCE, 2022–2029 (USD MILLION)
TABLE 130 FRANCE: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY INDICATION, 2022–2029 (USD MILLION)
TABLE 131 FRANCE: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY END USER, 2022–2029 (USD MILLION)
10.3.5 ITALY
10.3.5.1 Growth in biotech sector to drive market
TABLE 132 ITALY: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 133 ITALY: AUTOLOGOUS NON-STEM CELL THERAPIES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 134 ITALY: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY SOURCE, 2022–2029 (USD MILLION)
TABLE 135 ITALY: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY INDICATION, 2022–2029 (USD MILLION)
TABLE 136 ITALY: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY END USER, 2022–2029 (USD MILLION)
10.3.6 SPAIN
10.3.6.1 Rising focus on stem cell banking to support market growth
TABLE 137 SPAIN: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 138 SPAIN: AUTOLOGOUS NON-STEM CELL THERAPIES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 139 SPAIN: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY SOURCE, 2022–2029 (USD MILLION)
TABLE 140 SPAIN: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY INDICATION, 2022–2029 (USD MILLION)
TABLE 141 SPAIN: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY END USER, 2022–2029 (USD MILLION)
10.3.7 REST OF EUROPE
TABLE 142 REST OF EUROPE: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 143 REST OF EUROPE: AUTOLOGOUS NON-STEM CELL THERAPIES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 144 REST OF EUROPE: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY SOURCE, 2022–2029 (USD MILLION)
TABLE 145 REST OF EUROPE: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY INDICATION, 2022–2029 (USD MILLION)
TABLE 146 REST OF EUROPE: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY END USER, 2022–2029 (USD MILLION)
10.4 ASIA PACIFIC
10.4.1 ASIA PACIFIC: RECESSION IMPACT
FIGURE 32 ASIA PACIFIC: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SNAPSHOT
TABLE 147 ASIA PACIFIC: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 148 ASIA PACIFIC: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 149 ASIA PACIFIC: AUTOLOGOUS NON-STEM CELL THERAPIES, BY TYPE, 2022–2029 (USD MILLION)
TABLE 150 ASIA PACIFIC: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY SOURCE, 2022–2029 (USD MILLION)
TABLE 151 ASIA PACIFIC: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY INDICATION, 2022–2029 (USD MILLION)
TABLE 152 ASIA PACIFIC: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY END USER, 2022–2029 (USD MILLION)
10.4.2 JAPAN
10.4.2.1 Increasing product approvals to drive market
TABLE 153 JAPAN: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 154 JAPAN: AUTOLOGOUS NON-STEM CELL THERAPIES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 155 JAPAN: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY SOURCE, 2022–2029 (USD MILLION)
TABLE 156 JAPAN: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY INDICATION, 2022–2029 (USD MILLION)
TABLE 157 JAPAN: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY END USER, 2022–2029 (USD MILLION)
10.4.3 CHINA
10.4.3.1 Rising number of CAR T-cell clinical trials to support market growth
TABLE 158 CHINA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 159 CHINA: AUTOLOGOUS NON-STEM CELL THERAPIES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 160 CHINA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY SOURCE, 2022–2029 (USD MILLION)
TABLE 161 CHINA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY INDICATION, 2022–2029 (USD MILLION)
TABLE 162 CHINA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY END USER, 2022–2029 (USD MILLION)
10.4.4 INDIA
10.4.4.1 Rising incidence of cancer and growing focus on product commercialization to boost demand
TABLE 163 INDIA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 164 INDIA: AUTOLOGOUS NON-STEM CELL THERAPIES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 165 INDIA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY SOURCE, 2022–2029 (USD MILLION)
TABLE 166 INDIA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY INDICATION, 2022–2029 (USD MILLION)
TABLE 167 INDIA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY END USER, 2022–2029 (USD MILLION)
10.4.5 SOUTH KOREA
10.4.5.1 Rising growth in biopharmaceutical industry to drive market
TABLE 168 SOUTH KOREA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 169 SOUTH KOREA: AUTOLOGOUS NON-STEM CELL THERAPIES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 170 SOUTH KOREA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY SOURCE, 2022–2029 (USD MILLION)
TABLE 171 SOUTH KOREA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY INDICATION, 2022–2029 (USD MILLION)
TABLE 172 SOUTH KOREA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY END USER, 2022–2029 (USD MILLION)
10.4.6 REST OF ASIA PACIFIC
TABLE 173 REST OF ASIA PACIFIC: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 174 REST OF ASIA PACIFIC: AUTOLOGOUS NON-STEM CELL THERAPIES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 175 REST OF ASIA PACIFIC: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY SOURCE, 2022–2029 (USD MILLION)
TABLE 176 REST OF ASIA PACIFIC: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY INDICATION, 2022–2029 (USD MILLION)
TABLE 177 REST OF ASIA PACIFIC: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY END USER, 2022–2029 (USD MILLION)
10.5 LATIN AMERICA
10.5.1 LATIN AMERICA: RECESSION IMPACT
TABLE 178 LATIN AMERICA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 179 LATIN AMERICA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 180 LATIN AMERICA: AUTOLOGOUS NON-STEM CELL THERAPIES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 181 LATIN AMERICA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY SOURCE, 2022–2029 (USD MILLION)
TABLE 182 LATIN AMERICA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY INDICATION, 2022–2029 (USD MILLION)
TABLE 183 LATIN AMERICA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY END USER, 2022–2029 (USD MILLION)
10.5.2 BRAZIL
10.5.2.1 High expenditure on healthcare to support market growth
TABLE 184 BRAZIL: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 185 BRAZIL: AUTOLOGOUS NON-STEM CELL THERAPIES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 186 BRAZIL: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY SOURCE, 2022–2029 (USD MILLION)
TABLE 187 BRAZIL: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY INDICATION, 2022–2029 (USD MILLION)
TABLE 188 BRAZIL: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY END USER, 2022–2029 (USD MILLION)
10.5.3 MEXICO
10.5.3.1 Low operating costs to support market growth
TABLE 189 MEXICO: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 190 MEXICO: AUTOLOGOUS NON-STEM CELL THERAPIES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 191 MEXICO: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY SOURCE, 2022–2029 (USD MILLION)
TABLE 192 MEXICO: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY INDICATION, 2022–2029 (USD MILLION)
TABLE 193 MEXICO: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY END USER, 2022–2029 (USD MILLION)
10.5.4 ARGENTINA
10.5.4.1 Funding for stem cell research to drive market
TABLE 194 ARGENTINA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 195 ARGENTINA: AUTOLOGOUS NON-STEM CELL THERAPIES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 196 ARGENTINA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY SOURCE, 2022–2029 (USD MILLION)
TABLE 197 ARGENTINA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY INDICATION, 2022–2029 (USD MILLION)
TABLE 198 ARGENTINA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY END USER, 2022–2029 (USD MILLION)
10.5.5 REST OF LATIN AMERICA
TABLE 199 REST OF LATIN AMERICA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 200 REST OF LATIN AMERICA: AUTOLOGOUS NON-STEM CELL THERAPIES, BY TYPE, 2022–2029 (USD MILLION)
TABLE 201 REST OF LATIN AMERICA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY SOURCE, 2022–2029 (USD MILLION)
TABLE 202 REST OF LATIN AMERICA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY INDICATION, 2022–2029 (USD MILLION)
TABLE 203 REST OF LATIN AMERICA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY END USER, 2022–2029 (USD MILLION)
10.6 MIDDLE EAST
10.6.1 MIDDLE EAST: RECESSION IMPACT
TABLE 204 MIDDLE EAST: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 205 MIDDLE EAST: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 206 MIDDLE EAST: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 207 MIDDLE EAST: AUTOLOGOUS NON-STEM CELL THERAPIES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 208 MIDDLE EAST: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY SOURCE, 2022–2029 (USD MILLION)
TABLE 209 MIDDLE EAST: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY INDICATION, 2022–2029 (USD MILLION)
TABLE 210 MIDDLE EAST: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY END USER, 2022–2029 (USD MILLION)
10.6.2 GCC COUNTRIES
TABLE 211 GCC COUNTRIES: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 212 GCC COUNTRIES: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 213 GCC COUNTRIES: AUTOLOGOUS NON-STEM CELL THERAPIES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 214 GCC COUNTRIES: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY SOURCE, 2022–2029 (USD MILLION)
TABLE 215 GCC COUNTRIES: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY INDICATION, 2022–2029 (USD MILLION)
TABLE 216 GCC COUNTRIES: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY END USER, 2022–2029 (USD MILLION)
10.6.2.1 Kingdom of Saudi Arabia (KSA)
10.6.2.1.1 Growing demand for novel therapeutics to boost demand
TABLE 217 KINGDOM OF SAUDI ARABIA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 218 KINGDOM OF SAUDI ARABIA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR AUTOLOGOUS NON-STEM CELL THERAPIES, BY TYPE, 2022–2029 (USD MILLION)
TABLE 219 KINGDOM OF SAUDI ARABIA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY SOURCE, 2022–2029 (USD MILLION)
TABLE 220 KINGDOM OF SAUDI ARABIA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY INDICATION, 2022–2029 (USD MILLION)
TABLE 221 KINGDOM OF SAUDI ARABIA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY END USER, 2022–2029 (USD MILLION)
10.6.2.2 United Arab Emirates (UAE)
10.6.2.2.1 Growing focus on automation of platforms to fuel market
TABLE 222 UNITED ARAB EMIRATES: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 223 UNITED ARAB EMIRATES: AUTOLOGOUS NON-STEM CELL THERAPIES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 224 UNITED ARAB EMIRATES: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY SOURCE, 2022–2029 (USD MILLION)
TABLE 225 UNITED ARAB EMIRATES: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY INDICATION, 2022–2029 (USD MILLION)
TABLE 226 UNITED ARAB EMIRATES: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY END USER, 2022–2029 (USD MILLION)
10.6.2.3 Other GCC Countries
TABLE 227 OTHER GCC COUNTRIES: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 228 OTHER GCC COUNTRIES: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR AUTOLOGOUS NON-STEM CELL THERAPIES, BY TYPE, 2022–2029 (USD MILLION)
TABLE 229 OTHER GCC COUNTRIES: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY SOURCE, 2022–2029 (USD MILLION)
TABLE 230 OTHER GCC COUNTRIES: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY INDICATION, 2022–2029 (USD MILLION)
TABLE 231 OTHER GCC COUNTRIES: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY END USER, 2022–2029 (USD MILLION)
10.6.2.4 Rest of the Middle East
TABLE 232 REST OF MIDDLE EAST: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 233 REST OF MIDDLE EAST: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR AUTOLOGOUS NON-STEM CELL THERAPIES, BY TYPE, 2022–2029 (USD MILLION)
TABLE 234 REST OF MIDDLE EAST: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY SOURCE, 2022–2029 (USD MILLION)
TABLE 235 REST OF MIDDLE EAST: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY INDICATION, 2022–2029 (USD MILLION)
TABLE 236 REST OF MIDDLE EAST: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY END USER, 2022–2029 (USD MILLION)
10.7 AFRICA
10.7.1 IMPROVEMENTS IN HEALTHCARE INFRASTRUCTURE TO SUPPORT MARKET GROWTH
TABLE 237 AFRICA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 238 AFRICA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR AUTOLOGOUS NON-STEM CELL THERAPIES, BY TYPE, 2022–2029 (USD MILLION)
TABLE 239 AFRICA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY SOURCE, 2022–2029 (USD MILLION)
TABLE 240 AFRICA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY INDICATION, 2022–2029 (USD MILLION)
TABLE 241 AFRICA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY END USER, 2022–2029 (USD MILLION)
10.7.2 AFRICA: RECESSION IMPACT
11 COMPETITIVE LANDSCAPE
11.1 OVERVIEW
11.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
FIGURE 33 STRATEGIES ADOPTED BY KEY PLAYERS
11.3 REVENUE ANALYSIS
FIGURE 34 REVENUE ANALYSIS OF KEY PLAYERS, 2021?2023
11.4 MARKET SHARE ANALYSIS
FIGURE 35 AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES: MARKET SHARE ANALYSIS, 2023 (TOP 3 PLAYERS)
TABLE 242 AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET: DEGREE OF COMPETITION
11.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
11.5.1 STARS
11.5.2 EMERGING LEADERS
11.5.3 PERVASIVE PLAYERS
11.5.4 PARTICIPANTS
FIGURE 36 AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2023
11.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023
11.5.5.1 Company footprint
FIGURE 37 AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET: COMPANY FOOTPRINT
11.5.5.2 Region footprint
TABLE 243 AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET: REGION FOOTPRINT
11.5.5.3 Type footprint
TABLE 244 AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET: TYPE FOOTPRINT
11.5.5.4 Source footprint
TABLE 245 AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET: SOURCE FOOTPRINT
11.5.5.5 Indication footprint
TABLE 246 AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET: INDICATION FOOTPRINT
11.6 COMPANY EVALUATION MATRIX: START-UPS/SMES, 2023
11.6.1 PROGRESSIVE COMPANIES
11.6.2 RESPONSIVE COMPANIES
11.6.3 DYNAMIC COMPANIES
11.6.4 STARTING BLOCKS
FIGURE 38 AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET: COMPANY EVALUATION MATRIX (START-UPS/SMES), 2023
11.6.5 COMPETITIVE BENCHMARKING: START-UPS/SMES, 2023
TABLE 247 AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET: DETAILED LIST OF KEY START-UPS/SMES
FIGURE 39 AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET: OVERALL FOOTPRINT FOR START-UPS/SMES
TABLE 248 AUTOLOGOUS STEM-CELL & NON-STEM CELL THERAPY MARKET: COMPETITIVE BENCHMARKING OF START-UPS/SMES
11.7 COMPANY VALUATION & FINANCIAL METRICS
FIGURE 40 EV/EBITDA OF KEY VENDORS
FIGURE 41 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS
11.8 BRAND/PRODUCT COMPARISON
TABLE 249 BRAND/PRODUCT COMPARISON FOR AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES (APPROVED THERAPIES)
11.8.1 GILEAD SCIENCES, INC.
11.8.2 BRISTOL-MYERS SQUIBB COMPANY
11.8.3 NOVARTIS AG
11.9 COMPETITIVE SCENARIO
11.9.1 PRODUCT LAUNCHES & APPROVALS
TABLE 250 AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021–MAY 2024
11.9.2 DEALS
TABLE 251 AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET: DEALS, JANUARY 2021–MAY 2024
TABLE 252 AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET: EXPANSIONS, JANUARY 2021–MAY 2024
11.9.3 OTHER DEVELOPMENTS
TABLE 253 AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPY MARKET: OTHER DEVELOPMENTS, JANUARY 2021–MAY 2024
12 COMPANY PROFILES
12.1 KEY PLAYERS
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
12.1.1 BRISTOL-MYERS SQUIBB COMPANY
TABLE 254 BRISTOL-MYERS SQUIBB COMPANY: COMPANY OVERVIEW
FIGURE 42 BRISTOL-MYERS SQUIBB COMPANY: COMPANY SNAPSHOT (2023)
TABLE 255 BRISTOL-MYERS SQUIBB COMPANY: PRODUCTS OFFERED
TABLE 256 BRISTOL-MYERS SQUIBB COMPANY: PRODUCT APPROVALS, JANUARY 2021?MAY 2024
TABLE 257 BRISTOL-MYERS SQUIBB COMPANY: DEALS, JANUARY 2021? MAY 2024
12.1.2 GILEAD SCIENCES, INC.
TABLE 258 GILEAD SCIENCES, INC.: COMPANY OVERVIEW
FIGURE 43 GILEAD SCIENCES, INC.: COMPANY SNAPSHOT (2023)
TABLE 259 GILEAD SCIENCES, INC.: PRODUCTS OFFERED
TABLE 260 GILEAD SCIENCES, INC.: PRODUCT APPROVALS, JANUARY 2021?MAY 2024
TABLE 261 GILEAD SCIENCES, INC.: DEALS, JANUARY 2021?MAY 2024
TABLE 262 GILEAD SCIENCES, INC.: OTHER DEVELOPMENTS, JANUARY 2021–MAY 2024
12.1.3 NOVARTIS AG
TABLE 263 NOVARTIS AG: COMPANY OVERVIEW
FIGURE 44 NOVARTIS AG: COMPANY SNAPSHOT
TABLE 264 NOVARTIS AG: PRODUCTS OFFERED
TABLE 265 NOVARTIS AG: PRODUCT LAUNCHES & APPROVALS,
JANUARY 2021?MAY 2024
TABLE 266 NOVARTIS AG: EXPANSIONS, JANUARY 2021?MAY 2024
TABLE 267 NOVARTIS AG: OTHER DEVELOPMENTS, JANUARY 2021?MAY 2024
12.1.4 JOHNSON & JOHNSON
TABLE 268 JOHNSON & JOHNSON: COMPANY OVERVIEW
FIGURE 45 JOHNSON & JOHNSON: COMPANY SNAPSHOT (2023)
TABLE 269 JOHNSON & JOHNSON: PRODUCTS OFFERED
TABLE 270 JOHNSON & JOHNSON: PRODUCT APPROVALS, JANUARY 2021?MAY 2024
TABLE 271 JOHNSON & JOHNSON: DEALS, JANUARY 2021?MAY 2024
12.1.5 VERICEL CORPORATION
TABLE 272 VERICEL CORPORATION: COMPANY OVERVIEW
FIGURE 46 VERICEL CORPORATION: COMPANY SNAPSHOT (2023)
TABLE 273 VERICEL CORPORATION: PRODUCTS OFFERED
TABLE 274 VERICEL CORPORATION: EXPANSIONS, JANUARY 2021?MAY 2024
12.1.6 IOVANCE BIOTHERAPEUTICS, INC.
TABLE 275 IOVANCE BIOTHERAPEUTICS, INC.: COMPANY OVERVIEW
FIGURE 47 IOVANCE BIOTHERAPEUTICS, INC.: COMPANY SNAPSHOT (2023)
TABLE 276 IOVANCE BIOTHERAPEUTICS, INC.: PRODUCTS OFFERED
TABLE 277 IOVANCE BIOTHERAPEUTICS, INC.: PRODUCT APPROVALS, JANUARY 2021?MAY 2024
TABLE 278 IOVANCE BIOTHERAPEUTICS, INC.: EXPANSIONS, JANUARY 2021?MAY 2024
12.1.7 JW (CAYMAN) THERAPEUTICS CO. LTD
TABLE 279 JW (CAYMAN) THERAPEUTICS CO. LTD: COMPANY OVERVIEW
FIGURE 48 JW (CAYMAN) THERAPEUTICS CO. LTD: COMPANY SNAPSHOT (2023)
TABLE 280 JW (CAYMAN) THERAPEUTICS CO. LTD: PRODUCTS OFFERED
TABLE 281 JW (CAYMAN) THERAPEUTICS CO. LTD: PRODUCT APPROVALS, JANUARY 2021?MAY 2024
TABLE 282 JW (CAYMAN) THERAPEUTICS CO. LTD: DEALS
12.1.8 PHARMICELL CO., LTD.
TABLE 283 PHARMICELL CO., LTD.: COMPANY OVERVIEW
TABLE 284 PHARMICELL CO., LTD: PRODUCTS OFFERED
12.1.9 HOLOSTEM S.R.L.
TABLE 285 HOLOSTEM S.R.L.: COMPANY OVERVIEW
TABLE 286 HOLOSTEM SRL: PRODUCTS OFFERED
12.1.10 HEALIVA SA
TABLE 287 HEALIVA SA: COMPANY OVERVIEW
TABLE 288 HEALIVA SA: PRODUCTS OFFERED
TABLE 289 HEALIVA SA: DEALS
12.1.11 APAC BIOTECH
TABLE 290 APAC BIOTECH: COMPANY OVERVIEW
TABLE 291 APAC BIOTECH: PRODUCTS OFFERED
12.1.12 IMMUNOADOPTIVE CELL THERAPY PRIVATE LIMITED (IMMUNOACT)
TABLE 292 IMMUNOADOPTIVE CELL THERAPY PRIVATE LIMITED: COMPANY OVERVIEW
TABLE 293 IMMUNOADOPTIVE CELL THERAPY PRIVATE LIMITED: PRODUCTS OFFERED
TABLE 294 IMMUNOADOPTIVE CELL THERAPY PRIVATE LIMITED: DEALS
TABLE 295 IMMUNOADOPTIVE CELL THERAPY PRIVATE LIMITED: OTHER DEVELOPMENTS, JANUARY 2021–MAY 2024
12.1.13 REGROW BIOSCIENCES PVT LTD.
TABLE 296 REGROW BIOSCIENCES PVT LTD.: COMPANY OVERVIEW
TABLE 297 REGROW BIOSCIENCES PVT LTD.: PRODUCTS OFFERED
TABLE 298 REGROW BIOSCIENCES PVT LTD.: PRODUCT APPROVALS, JANUARY 2021?MAY 2024
12.1.14 TEGO SCIENCE, INC.
TABLE 299 TEGO SCIENCE, INC.: COMPANY OVERVIEW
TABLE 300 TEGO SCIENCE, INC.: PRODUCTS OFFERED
12.1.15 CARSGEN THERAPEUTICS HOLDINGS LIMITED
TABLE 301 CARSGEN THERAPEUTICS HOLDINGS LIMITED: COMPANY OVERVIEW
TABLE 302 CARSGEN THERAPEUTICS HOLDINGS LIMITED: PRODUCTS OFFERED
TABLE 303 CARSGEN THERAPEUTICS HOLDINGS LIMITED: PRODUCT APPROVALS, JANUARY 2021?MAY 2024
TABLE 304 CARSGEN THERAPEUTICS HOLDINGS LIMITED: EXPANSIONS
TABLE 305 CARSGEN THERAPEUTICS HOLDINGS LIMITED: DEALS
12.1.16 IASO BIOTHERAPEUTICS
TABLE 306 IASO BIOTHERAPEUTICS: COMPANY OVERVIEW
TABLE 307 IASO BIOTHERAPEUTICS: PRODUCTS OFFERED
TABLE 308 IASO BIOTHERAPEUTICS: PRODUCT APPROVALS
TABLE 309 IASO BIOTHERAPEUTICS: DEALS
12.1.17 ANTEROGEN.CO.,LTD.
TABLE 310 ANTEROGEN.CO.,LTD.: COMPANY OVERVIEW
TABLE 311 ANTEROGEN.CO.,LTD.: PRODUCTS OFFERED
12.1.18 GREEN CROSS HOLDINGS CO., LTD. (GC CELL)
TABLE 312 GREEN CROSS HOLDINGS CO., LTD. (GC CELL): COMPANY OVERVIEW
FIGURE 49 GREEN CROSS HOLDINGS CO., LTD. (GC CELL): COMPANY OVERVIEW (2023)
TABLE 313 GREEN CROSS HOLDINGS CO., LTD. (GC CELL): PRODUCTS OFFERED
TABLE 314 GREEN CROSS HOLDINGS CO., LTD. (GC CELL): DEALS
12.1.19 SANPOWER GROUP CO., LTD. (DENDREON PHARMACEUTICALS LLC.)
TABLE 315 SANPOWER GROUP CO., LTD.: COMPANY OVERVIEW
TABLE 316 SANPOWER GROUP CO., LTD. (DENDREON): PRODUCTS OFFERED
12.2 OTHER PLAYERS
12.2.1 PROKIDNEY CORP.
TABLE 317 PROKIDNEY CORP.: COMPANY OVERVIEW
12.2.2 BIOCARDIA, INC.
TABLE 318 BIOCARDIA, INC.: COMPANY OVERVIEW
12.2.3 NEUROPLAST B.V.
TABLE 319 NEUROPLAST B.V.: COMPANY OVERVIEW
12.2.4 ADAPTIMMUNE THERAPEUTICS PLC
TABLE 320 ADAPTIMMUNE THERAPEUTICS PLC.: COMPANY OVERVIEW
12.2.5 AGONOX, INC.
TABLE 321 AGONIX, INC.: COMPANY OVERVIEW
12.2.6 KYVERNA THERAPEUTICS, INC.
TABLE 322 KYVERNA THERAPEUTICS, INC.: COMPANY OVERVIEW
12.2.7 OBSIDIAN THERAPEUTICS, INC.
TABLE 323 OBSIDIAN THERAPEUTICS, INC.: COMPANY OVERVIEW
12.2.8 AVOTRES INC.
TABLE 324 AVOTRES, INC.: COMPANY OVERVIEW
12.2.9 CORESTEMCHEMON INC.
TABLE 325 CORESTEMCHEMON INC.: COMPANY OVERVIEW
12.2.10 JUVENTAS CELL THERAPY LTD.
TABLE 326 JUVENTAS CELL THERAPY LTD.: COMPANY OVERVIEW
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.
13 APPENDIX
13.1 DISCUSSION GUIDE
13.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
13.3 CUSTOMIZATION OPTIONS
13.4 RELATED REPORTS
13.5 AUTHOR DETAILS
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS & EXCLUSIONS
1.3 MARKET SCOPE
1.3.1 MARKET SEGMENTATION
1.3.2 REGIONAL SEGMENTATION
FIGURE 1 REGIONS COVERED
1.3.3 YEARS CONSIDERED
1.3.4 CURRENCY CONSIDERED
1.4 STAKEHOLDERS
1.5 SUMMARY OF CHANGES
1.6 RECESSION IMPACT
2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
FIGURE 2 RESEARCH DESIGN
2.1.1 SECONDARY DATA
2.1.2 PRIMARY DATA
FIGURE 3 BREAKDOWN OF PRIMARIES: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS
2.2 MARKET SIZE ESTIMATION
FIGURE 4 AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET: MARKET SIZE ESTIMATION FOR SUPPLY-SIDE ANALYSIS, 2023
FIGURE 5 AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET: REVENUE SHARE ANALYSIS, 2023
FIGURE 6 GILEAD SCIENCES, INC.: REVENUE SHARE ANALYSIS, 2023
2.3 PRIMARY INSIGHTS
FIGURE 7 VALIDATION FROM PRIMARY EXPERTS
2.3.1 SEGMENTAL ASSESSMENT
FIGURE 8 MARKET SIZE ESTIMATION: TOP-DOWN APPROACH
2.4 GROWTH FORECAST
FIGURE 9 AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET: CAGR PROJECTIONS (2024–2029)
FIGURE 10 GROWTH ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
2.5 VOLUME ESTIMATION
2.6 MARKET BREAKDOWN & DATA TRIANGULATION
FIGURE 11 DATA TRIANGULATION METHODOLOGY
2.7 STUDY ASSUMPTIONS
2.8 RISK ANALYSIS
TABLE 1 AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET: RISK ASSESSMENT ANALYSIS
2.9 RECESSION IMPACT ANALYSIS
TABLE 2 GLOBAL INFLATION RATE PROJECTIONS, 2021–2028 (% GROWTH)
3 EXECUTIVE SUMMARY
FIGURE 12 AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY TYPE, 2024 VS. 2029 (USD MILLION)
FIGURE 13 AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY INDICATION, 2024 VS. 2029 (USD MILLION)
FIGURE 14 AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY SOURCE, 2024 VS. 2029 (USD MILLION)
FIGURE 15 AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY END USER, 2024?2029
FIGURE 16 GEOGRAPHICAL SNAPSHOT OF AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET
4 PREMIUM INSIGHTS
4.1 AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET OVERVIEW
FIGURE 17 RISING REGULATORY APPROVALS FOR CAR T-CELL THERAPIES TO DRIVE MARKET
4.2 NORTH AMERICA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY TYPE AND COUNTRY (2023)
FIGURE 18 AUTOLOGOUS NON-STEM CELL THERAPIES SEGMENT ACCOUNTED FOR LARGEST MARKET SHARE IN 2023
4.3 AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SHARE, BY SOURCE, 2024 VS. 2029
FIGURE 19 T-CELLS SOURCE SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD
4.4 AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SHARE, BY INDICATION, 2023
FIGURE 20 CANCER INDICATION SEGMENT TO ACCOUNT FOR LARGEST MARKET SHARE IN 2023
4.5 AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
FIGURE 21 ASIA PACIFIC REGION TO GROW AT HIGHEST CAGR DURING FORECAST PERIOD
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
FIGURE 22 AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
TABLE 3 AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET: IMPACT ANALYSIS
5.2.1 DRIVERS
5.2.1.1 Rising approvals for CAR T-cell therapies
TABLE 4 APPROVED AUTOLOGOUS CAR T-CELL THERAPIES
5.2.1.2 Increasing R&D investments in autologous therapeutics
5.2.1.3 Increasing demand for personalized medicine
5.2.2 RESTRAINTS
5.2.2.1 Uptake of allogeneic cell-based therapies as substitutes
5.2.3 OPPORTUNITIES
5.2.3.1 Rising outsourcing of manufacturing activities
5.2.3.2 Adoption of closed automated systems
5.2.4 CHALLENGES
5.2.4.1 Stringent regulatory guidelines and reimbursement challenges
5.2.4.2 Issues associated with scalable manufacturing
5.3 SUPPLY CHAIN ANALYSIS
FIGURE 23 SUPPLY CHAIN ANALYSIS: DIRECT DISTRIBUTION STRATEGY PREFERRED BY PROMINENT COMPANIES
5.4 TECHNOLOGY ANALYSIS
5.4.1 KEY TECHNOLOGIES
5.4.1.1 Genome editing
5.4.1.2 Synthetic biology
5.4.2 COMPLEMENTARY TECHNOLOGIES
5.4.2.1 Process analytical technology (PAT)
5.4.2.2 Point-of-care manufacturing
5.5 VALUE CHAIN ANALYSIS
FIGURE 24 VALUE CHAIN ANALYSIS—MAXIMUM VALUE IS ADDED DURING THERAPY MANUFACTURING PHASE
5.6 PRICING ANALYSIS
TABLE 5 AVERAGE SELLING PRICE FOR LEADING AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPEUTIC DRUGS
TABLE 6 AVERAGE SELLING PRICE FOR MAJOR AUTOLOGOUS STEM CELL AND NON-STEM CELL BASED THERAPEUTIC DRUGS, BY REGION
5.7 ECOSYSTEM ANALYSIS
5.7.1 ROLE IN ECOSYSTEM
5.8 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
FIGURE 26 REVENUE SHIFT AND NEW REVENUE POCKETS FOR AUTOLOGOUS STEM CELL AND NON-STEM CELL THERAPY MARKET MANUFACTURERS
5.9 PATENT ANALYSIS
5.9.1 PATENT ANALYSIS: AUTOLOGOUS CAR-T THERAPIES
FIGURE 27 PATENT APPLICATIONS FOR AUTOLOGOUS CAR-T THERAPIES, JANUARY 2013–OCTOBER 2023
5.9.2 PATENT ANALYSIS: TIL THERAPY
FIGURE 28 PATENT APPLICATIONS FOR TIL THERAPIES, JANUARY 2013–OCTOBER 2023
5.10 KEY CONFERENCES & EVENTS, 2024?2025
TABLE 7 AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET: LIST OF CONFERENCES & EVENTS
5.11 REGULATORY LANDSCAPE
5.11.1 REGULATORY ANALYSIS
5.11.2 NORTH AMERICA
5.11.2.1 US
5.11.2.2 Canada
5.11.3 EUROPE
5.11.3.1 Germany
5.11.3.2 UK
5.11.3.3 Rest of Europe
5.11.4 ASIA PACIFIC
5.11.4.1 China
5.11.4.2 Japan
5.11.4.3 South Korea
5.11.4.4 Australia
5.11.4.5 Rest of Asia Pacific
5.11.5 REGULATORY BODIES AND ORGANIZATIONS
TABLE 8 NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 9 EUROPE: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 10 ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 11 LATIN AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 12 MIDDLE EAST & AFRICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.12 PORTER’S FIVE FORCES ANALYSIS
FIGURE 29 AUTOLOGOUS STEM CELL & NON-STEM CELL MARKET: PORTER'S FIVE FORCE ANALYSIS
TABLE 13 PORTER’S FIVE FORCES ANALYSIS
5.12.1 DEGREE OF COMPETITION
5.12.2 BARGAINING POWER OF SUPPLIERS
5.12.3 BARGAINING POWER OF BUYERS
5.12.4 THREAT OF SUBSTITUTES
5.12.5 THREAT OF NEW ENTRANTS
5.13 KEY STAKEHOLDERS & BUYING CRITERIA
FIGURE 30 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY END USER
5.14 KEY BUYING CRITERIA
5.14.1 BUYING CRITERIA OF END USERS FOR AUTOLOGOUS STEM CELL AND NON-STEM CELL THERAPEUTIC PRODUCTS
5.14.2 BUYING CRITERIA FOR AUTOLOGOUS STEM CELL AND NON-STEM CELL THERAPEUTIC PRODUCTS, BY END USER
5.15 INVESTMENT AND FUNDING SCENARIO
5.16 CASE STUDY ANALYSIS
5.16.1 CASE STUDY 1
5.16.1.1 Comparative Analysis of Cupistem Efficacy in Treatment of Crohn's Perianal Fistulas
5.16.2 CASE STUDY 2
5.16.2.1 Evaluating Lenzumestrocel (Neuronata-R) in Amyotrophic Lateral Sclerosis: The ALSUMMIT Phase III Trial Protocol
5.16.3 CASE STUDY 3
5.16.3.1 Stemirac Stem Cell Therapy for Traumatic Spinal Cord Injury
5.16.4 CASE STUDY 4
5.16.4.1 Efficacy and Safety of Holoclar in Limbal Stem Cell Deficiency
6 AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY TYPE
6.1 INTRODUCTION
TABLE 14 AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 15 AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY TYPE, 2022–2029 (UNITS)
6.2 AUTOLOGOUS STEM CELL THERAPIES
6.2.1 RISING INCIDENCE OF CHRONIC DISEASES TO DRIVE MARKET
TABLE 16 AUTOLOGOUS STEM CELL THERAPIES MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 17 NORTH AMERICA: AUTOLOGOUS STEM CELL THERAPIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 18 EUROPE: AUTOLOGOUS STEM CELL THERAPIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 19 ASIA PACIFIC: AUTOLOGOUS STEM CELL MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 20 LATIN AMERICA: AUTOLOGOUS STEM CELL THERAPIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 21 MIDDLE EAST: AUTOLOGOUS STEM CELL MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 22 GCC COUNTRIES: AUTOLOGOUS STEM CELL MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
6.3 AUTOLOGOUS NON-STEM CELL THERAPIES
TABLE 23 AUTOLOGOUS NON-STEM CELL THERAPIES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 24 AUTOLOGOUS NON-STEM CELL THERAPIES MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 25 NORTH AMERICA: AUTOLOGOUS NON-STEM CELL THERAPIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 26 EUROPE: AUTOLOGOUS NON-STEM CELL THERAPIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 27 ASIA PACIFIC: AUTOLOGOUS NON-STEM CELL THERAPIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
6.4 CAR T-CELL THERAPIES
6.4.1 GROWING APPROVAL OF AUTOLOGOUS CAR T-CELL THERAPIES TO BOOST GROWTH
TABLE 28 CAR T-CELL THERAPIES MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 29 NORTH AMERICA: CAR T-CELL THERAPIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 30 EUROPE: CAR T-CELL THERAPIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 31 ASIA PACIFIC: CAR T-CELL THERAPIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
6.5 TUMOR-INFILTRATING LYMPHOCYTES (TILS)
6.5.1 EMERGING POTENTIAL OF TIL IN CANCER TREATMENT TO BOOST DEMAND
TABLE 32 TUMOR-INFILTRATING LYMPHOCYTES MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 33 NORTH AMERICA: TUMOR-INFILTRATING LYMPHOCYTES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
7 AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY INDICATION
7.1 INTRODUCTION
TABLE 34 AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY INDICATION, 2022–2029 (USD MILLION)
7.2 CANCER INDICATION
7.2.1 RISING INCIDENCE OF CANCER AND GROWING DEMAND FOR THERAPEUTICS TO DRIVE MARKET
TABLE 35 AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKEY FOR CANCER INDICATIONS, BY REGION, 2022–2029 (USD MILLION)
TABLE 36 NORTH AMERICA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR CANCER INDICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 37 EUROPE: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR CANCER INDICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 38 ASIA PACIFIC: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR CANCER INDICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
7.3 MUSCULOSKELETAL INDICATION
7.3.1 GROWING INCIDENCE OF OSTEOARTHRITIS TO DRIVE MARKET
TABLE 39 AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR MUSCULOSKELETAL INDICATIONS, BY REGION, 2022–2029 (USD MILLION)
TABLE 40 NORTH AMERICA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR MUSCULOSKELETAL INDICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 41 EUROPE: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR MUSCULOSKELETAL INDICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 42 ASIA PACIFIC: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR MUSCULOSKELETAL INDICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 43 LATIN AMERICA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR MUSCULOSKELETAL INDICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 44 MIDDLE EAST: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR MUSCULOSKELETAL INDICATIONS, BY REGION, 2022–2029 (USD MILLION)
TABLE 45 GCC COUNTRIES: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR MUSCULOSKELETAL INDICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
7.4 DERMATOLOGY INDICATION
7.4.1 INCREASING PREVALENCE OF SKIN DISORDERS TO SUPPORT MARKET GROWTH
TABLE 46 AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR DERMATOLOGICAL INDICATIONS, BY REGION, 2022–2029 (USD MILLION)
TABLE 47 NORTH AMERICA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR DERMATOLOGICAL INDICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 48 EUROPE: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR DERMATOLOGICAL INDICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 49 ASIA PACIFIC: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR DERMATOLOGICAL INDICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 50 LATIN AMERICA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR DERMATOLOGICAL INDICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 51 MIDDLE EAST: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR DERMATOLOGICAL INDICATIONS, BY REGION, 2022–2029 (USD MILLION)
TABLE 52 GCC COUNTRIES: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR DERMATOLOGICAL INDICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
7.5 OTHER INDICATIONS
TABLE 53 AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR OTHER INDICATIONS, BY REGION, 2022–2029 (USD MILLION)
TABLE 54 NORTH AMERICA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 55 EUROPE: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 56 ASIA PACIFIC: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 57 LATIN AMERICA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 58 MIDDLE EAST: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR OTHER INDICATIONS, BY REGION, 2022–2029 (USD MILLION)
TABLE 59 GCC COUNTRIES: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
8 AUTOLOGOUS STEM CELL AND NON-STEM CELL THERAPIES MARKET, BY SOURCE
8.1 INTRODUCTION
TABLE 60 AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY SOURCE, 2022–2029 (USD MILLION)
8.2 T-CELLS
8.2.1 GROWING ADOPTION OF CAR T-CELL THERAPIES TO DRIVE MARKET
TABLE 61 AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR T-CELLS, BY REGION, 2022–2029 (USD MILLION)
TABLE 62 NORTH AMERICA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR T-CELLS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 63 EUROPE: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR T-CELLS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 64 ASIA PACIFIC: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR T-CELLS, BY COUNTRY, 2022–2029 (USD MILLION)
8.3 MESENCHYMAL STEM CELLS
8.3.1 HIGH UPTAKE IN DEVELOPMENT OF AUTOLOGOUS THERAPIES TO SUPPORT MARKET GROWTH
TABLE 65 AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR MESENCHYMAL STEM CELLS, BY REGION, 2022–2029 (USD MILLION)
TABLE 66 NORTH AMERICA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR MESENCHYMAL STEM CELLS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 67 EUROPE: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR MESENCHYMAL STEM CELLS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 68 ASIA PACIFIC: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR MESENCHYMAL STEM CELLS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 69 LATIN AMERICA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR MESENCHYMAL STEM CELLS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 70 MIDDLE EAST: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR MESENCHYMAL STEM CELLS, BY REGION, 2022–2029 (USD MILLION)
TABLE 71 GCC COUNTRIES: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR MESENCHYMAL STEM CELLS, BY COUNTRY, 2022–2029 (USD MILLION)
9 AUTOLOGOUS STEM-CELL & NON-STEM CELL THERAPIES MARKET, BY END USER
9.1 INTRODUCTION
TABLE 72 AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY END USER, 2022–2029 (USD MILLION)
9.2 HOSPITALS AND CLINICS
9.2.1 ABILITY TO UNDERTAKE APHERESIS PROCEDURES WITH ADVANCED HEALTHCARE INFRASTRUCTURE TO DRIVE MARKET
TABLE 73 AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR HOSPITALS AND CLINICS, BY REGION, 2022–2029 (USD MILLION)
TABLE 74 NORTH AMERICA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR HOSPITALS AND CLINICS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 75 EUROPE: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR HOSPITALS AND CLINICS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 76 ASIA PACIFIC: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR HOSPITALS AND CLINICS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 77 LATIN AMERICA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR HOSPITALS AND CLINICS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 78 MIDDLE EAST: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR HOSPITALS AND CLINICS, BY REGION, 2022–2029 (USD MILLION)
TABLE 79 GCC COUNTRIES: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR HOSPITALS AND CLINICS, BY COUNTRY, 2022–2029 (USD MILLION)
9.3 LONG-TERM CARE FACILITIES
9.3.1 RISING INCIDENCE OF CHRONIC DISEASES TO SUPPORT MARKET GROWTH
TABLE 80 AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR LONG-TERM CARE FACILITIES, BY REGION, 2022–2029 (USD MILLION)
TABLE 81 NORTH AMERICA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 82 EUROPE: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 83 ASIA PACIFIC: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 84 LATIN AMERICA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 85 MIDDLE EAST: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR LONG-TERM CARE FACILITIES, BY REGION, 2022–2029 (USD MILLION)
TABLE 86 GCC COUNTRIES: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2022–2029 (USD MILLION)
9.4 SPECIALTY CARE CENTERS
9.4.1 GROWING PREFERENCE FOR PERSONALIZED MEDICINE TO BOOST DEMAND
TABLE 87 AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR SPECIALTY CARE CENTERS, BY REGION, 2022–2029 (USD MILLION)
TABLE 88 NORTH AMERICA: AUTOLOGOUS STEM CELL & NON-STEM CELL FOR SPECIALTY CARE CENTERS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 89 EUROPE: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR SPECIALTY CARE CENTERS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 90 ASIA PACIFIC: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR SPECIALTY CARE CENTERS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 91 LATIN AMERICA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR SPECIALTY CARE CENTERS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 92 MIDDLE EAST: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR SPECIALTY CARE CENTERS, BY REGION, 2022–2029 (USD MILLION)
TABLE 93 GCC COUNTRIES: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR SPECIALTY CARE CENTERS, BY COUNTRY, 2022–2029 (USD MILLION)
10 AUTOLOGOUS STEM CELL AND NON-STEM STEM CELL THERAPIES MARKET, BY REGION
10.1 INTRODUCTION
TABLE 94 AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY REGION, 2022–2029 (USD MILLION)
10.2 NORTH AMERICA
10.2.1 NORTH AMERICA: RECESSION IMPACT
FIGURE 31 NORTH AMERICA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SNAPSHOT
TABLE 95 NORTH AMERICA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 96 NORTH AMERICA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 97 NORTH AMERICA: AUTOLOGOUS NON-STEM CELL THERAPIES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 98 NORTH AMERICA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY SOURCE, 2022–2029 (USD MILLION)
TABLE 99 NORTH AMERICA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY INDICATION, 2022–2029 (USD MILLION)
TABLE 100 NORTH AMERICA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY END USER, 2022–2029 (USD MILLION)
10.2.2 US
10.2.2.1 Rising R&D activities for stem cell therapies to drive market
TABLE 101 US: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 102 US: AUTOLOGOUS NON-STEM CELL THERAPIES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 103 US: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY SOURCE, 2022–2029 (USD MILLION)
TABLE 104 US: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY INDICATION, 2022–2029 (USD MILLION)
TABLE 105 US: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY END USER, 2022–2029 (USD MILLION)
10.2.3 CANADA
10.2.3.1 Rising government initiatives for regenerative medicine research to drive market
TABLE 106 CANADA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 107 CANADA: AUTOLOGOUS NON-STEM CELL THERAPIES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 108 CANADA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY SOURCE, 2022–2029 (USD MILLION)
TABLE 109 CANADA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY INDICATION, 2022–2029 (USD MILLION)
TABLE 110 CANADA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY END USER, 2022–2029 (USD MILLION)
10.3 EUROPE
10.3.1 EUROPE: RECESSION IMPACT
TABLE 111 EUROPE: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 112 EUROPE: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 113 EUROPE: AUTOLOGOUS NON-STEM CELL THERAPIES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 114 EUROPE: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY SOURCE, 2022–2029 (USD MILLION)
TABLE 115 EUROPE: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY INDICATION, 2022–2029 (USD MILLION)
TABLE 116 EUROPE: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY END USER, 2022–2029 (USD MILLION)
10.3.2 GERMANY
10.3.2.1 Rising focus on clinical research to drive market
TABLE 117 GERMANY: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 118 GERMANY: AUTOLOGOUS NON-STEM CELL THERAPIES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 119 GERMANY: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY SOURCE, 2022–2029 (USD MILLION)
TABLE 120 GERMANY: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY INDICATION, 2022–2029 (USD MILLION)
TABLE 121 GERMANY: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY END USER, 2022–2029 (USD MILLION)
10.3.3 UK
10.3.3.1 Rising technological advancements in automation to drive market
TABLE 122 UK: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 123 UK: AUTOLOGOUS NON-STEM CELL THERAPIES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 124 UK: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY SOURCE, 2022–2029 (USD MILLION)
TABLE 125 UK: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY INDICATION, 2022–2029 (USD MILLION)
TABLE 126 UK: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY END USER, 2022–2029 (USD MILLION)
10.3.4 FRANCE
10.3.4.1 Growing focus on cell & gene therapy initiatives to boost demand
TABLE 127 FRANCE: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 128 FRANCE: AUTOLOGOUS NON-STEM CELL THERAPIES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 129 FRANCE: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY SOURCE, 2022–2029 (USD MILLION)
TABLE 130 FRANCE: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY INDICATION, 2022–2029 (USD MILLION)
TABLE 131 FRANCE: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY END USER, 2022–2029 (USD MILLION)
10.3.5 ITALY
10.3.5.1 Growth in biotech sector to drive market
TABLE 132 ITALY: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 133 ITALY: AUTOLOGOUS NON-STEM CELL THERAPIES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 134 ITALY: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY SOURCE, 2022–2029 (USD MILLION)
TABLE 135 ITALY: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY INDICATION, 2022–2029 (USD MILLION)
TABLE 136 ITALY: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY END USER, 2022–2029 (USD MILLION)
10.3.6 SPAIN
10.3.6.1 Rising focus on stem cell banking to support market growth
TABLE 137 SPAIN: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 138 SPAIN: AUTOLOGOUS NON-STEM CELL THERAPIES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 139 SPAIN: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY SOURCE, 2022–2029 (USD MILLION)
TABLE 140 SPAIN: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY INDICATION, 2022–2029 (USD MILLION)
TABLE 141 SPAIN: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY END USER, 2022–2029 (USD MILLION)
10.3.7 REST OF EUROPE
TABLE 142 REST OF EUROPE: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 143 REST OF EUROPE: AUTOLOGOUS NON-STEM CELL THERAPIES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 144 REST OF EUROPE: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY SOURCE, 2022–2029 (USD MILLION)
TABLE 145 REST OF EUROPE: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY INDICATION, 2022–2029 (USD MILLION)
TABLE 146 REST OF EUROPE: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY END USER, 2022–2029 (USD MILLION)
10.4 ASIA PACIFIC
10.4.1 ASIA PACIFIC: RECESSION IMPACT
FIGURE 32 ASIA PACIFIC: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SNAPSHOT
TABLE 147 ASIA PACIFIC: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 148 ASIA PACIFIC: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 149 ASIA PACIFIC: AUTOLOGOUS NON-STEM CELL THERAPIES, BY TYPE, 2022–2029 (USD MILLION)
TABLE 150 ASIA PACIFIC: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY SOURCE, 2022–2029 (USD MILLION)
TABLE 151 ASIA PACIFIC: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY INDICATION, 2022–2029 (USD MILLION)
TABLE 152 ASIA PACIFIC: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY END USER, 2022–2029 (USD MILLION)
10.4.2 JAPAN
10.4.2.1 Increasing product approvals to drive market
TABLE 153 JAPAN: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 154 JAPAN: AUTOLOGOUS NON-STEM CELL THERAPIES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 155 JAPAN: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY SOURCE, 2022–2029 (USD MILLION)
TABLE 156 JAPAN: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY INDICATION, 2022–2029 (USD MILLION)
TABLE 157 JAPAN: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY END USER, 2022–2029 (USD MILLION)
10.4.3 CHINA
10.4.3.1 Rising number of CAR T-cell clinical trials to support market growth
TABLE 158 CHINA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 159 CHINA: AUTOLOGOUS NON-STEM CELL THERAPIES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 160 CHINA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY SOURCE, 2022–2029 (USD MILLION)
TABLE 161 CHINA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY INDICATION, 2022–2029 (USD MILLION)
TABLE 162 CHINA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY END USER, 2022–2029 (USD MILLION)
10.4.4 INDIA
10.4.4.1 Rising incidence of cancer and growing focus on product commercialization to boost demand
TABLE 163 INDIA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 164 INDIA: AUTOLOGOUS NON-STEM CELL THERAPIES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 165 INDIA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY SOURCE, 2022–2029 (USD MILLION)
TABLE 166 INDIA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY INDICATION, 2022–2029 (USD MILLION)
TABLE 167 INDIA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY END USER, 2022–2029 (USD MILLION)
10.4.5 SOUTH KOREA
10.4.5.1 Rising growth in biopharmaceutical industry to drive market
TABLE 168 SOUTH KOREA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 169 SOUTH KOREA: AUTOLOGOUS NON-STEM CELL THERAPIES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 170 SOUTH KOREA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY SOURCE, 2022–2029 (USD MILLION)
TABLE 171 SOUTH KOREA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY INDICATION, 2022–2029 (USD MILLION)
TABLE 172 SOUTH KOREA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY END USER, 2022–2029 (USD MILLION)
10.4.6 REST OF ASIA PACIFIC
TABLE 173 REST OF ASIA PACIFIC: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 174 REST OF ASIA PACIFIC: AUTOLOGOUS NON-STEM CELL THERAPIES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 175 REST OF ASIA PACIFIC: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY SOURCE, 2022–2029 (USD MILLION)
TABLE 176 REST OF ASIA PACIFIC: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY INDICATION, 2022–2029 (USD MILLION)
TABLE 177 REST OF ASIA PACIFIC: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY END USER, 2022–2029 (USD MILLION)
10.5 LATIN AMERICA
10.5.1 LATIN AMERICA: RECESSION IMPACT
TABLE 178 LATIN AMERICA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 179 LATIN AMERICA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 180 LATIN AMERICA: AUTOLOGOUS NON-STEM CELL THERAPIES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 181 LATIN AMERICA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY SOURCE, 2022–2029 (USD MILLION)
TABLE 182 LATIN AMERICA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY INDICATION, 2022–2029 (USD MILLION)
TABLE 183 LATIN AMERICA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY END USER, 2022–2029 (USD MILLION)
10.5.2 BRAZIL
10.5.2.1 High expenditure on healthcare to support market growth
TABLE 184 BRAZIL: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 185 BRAZIL: AUTOLOGOUS NON-STEM CELL THERAPIES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 186 BRAZIL: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY SOURCE, 2022–2029 (USD MILLION)
TABLE 187 BRAZIL: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY INDICATION, 2022–2029 (USD MILLION)
TABLE 188 BRAZIL: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY END USER, 2022–2029 (USD MILLION)
10.5.3 MEXICO
10.5.3.1 Low operating costs to support market growth
TABLE 189 MEXICO: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 190 MEXICO: AUTOLOGOUS NON-STEM CELL THERAPIES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 191 MEXICO: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY SOURCE, 2022–2029 (USD MILLION)
TABLE 192 MEXICO: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY INDICATION, 2022–2029 (USD MILLION)
TABLE 193 MEXICO: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY END USER, 2022–2029 (USD MILLION)
10.5.4 ARGENTINA
10.5.4.1 Funding for stem cell research to drive market
TABLE 194 ARGENTINA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 195 ARGENTINA: AUTOLOGOUS NON-STEM CELL THERAPIES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 196 ARGENTINA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY SOURCE, 2022–2029 (USD MILLION)
TABLE 197 ARGENTINA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY INDICATION, 2022–2029 (USD MILLION)
TABLE 198 ARGENTINA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY END USER, 2022–2029 (USD MILLION)
10.5.5 REST OF LATIN AMERICA
TABLE 199 REST OF LATIN AMERICA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 200 REST OF LATIN AMERICA: AUTOLOGOUS NON-STEM CELL THERAPIES, BY TYPE, 2022–2029 (USD MILLION)
TABLE 201 REST OF LATIN AMERICA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY SOURCE, 2022–2029 (USD MILLION)
TABLE 202 REST OF LATIN AMERICA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY INDICATION, 2022–2029 (USD MILLION)
TABLE 203 REST OF LATIN AMERICA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY END USER, 2022–2029 (USD MILLION)
10.6 MIDDLE EAST
10.6.1 MIDDLE EAST: RECESSION IMPACT
TABLE 204 MIDDLE EAST: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 205 MIDDLE EAST: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 206 MIDDLE EAST: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 207 MIDDLE EAST: AUTOLOGOUS NON-STEM CELL THERAPIES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 208 MIDDLE EAST: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY SOURCE, 2022–2029 (USD MILLION)
TABLE 209 MIDDLE EAST: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY INDICATION, 2022–2029 (USD MILLION)
TABLE 210 MIDDLE EAST: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY END USER, 2022–2029 (USD MILLION)
10.6.2 GCC COUNTRIES
TABLE 211 GCC COUNTRIES: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 212 GCC COUNTRIES: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 213 GCC COUNTRIES: AUTOLOGOUS NON-STEM CELL THERAPIES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 214 GCC COUNTRIES: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY SOURCE, 2022–2029 (USD MILLION)
TABLE 215 GCC COUNTRIES: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY INDICATION, 2022–2029 (USD MILLION)
TABLE 216 GCC COUNTRIES: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY END USER, 2022–2029 (USD MILLION)
10.6.2.1 Kingdom of Saudi Arabia (KSA)
10.6.2.1.1 Growing demand for novel therapeutics to boost demand
TABLE 217 KINGDOM OF SAUDI ARABIA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 218 KINGDOM OF SAUDI ARABIA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR AUTOLOGOUS NON-STEM CELL THERAPIES, BY TYPE, 2022–2029 (USD MILLION)
TABLE 219 KINGDOM OF SAUDI ARABIA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY SOURCE, 2022–2029 (USD MILLION)
TABLE 220 KINGDOM OF SAUDI ARABIA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY INDICATION, 2022–2029 (USD MILLION)
TABLE 221 KINGDOM OF SAUDI ARABIA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY END USER, 2022–2029 (USD MILLION)
10.6.2.2 United Arab Emirates (UAE)
10.6.2.2.1 Growing focus on automation of platforms to fuel market
TABLE 222 UNITED ARAB EMIRATES: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 223 UNITED ARAB EMIRATES: AUTOLOGOUS NON-STEM CELL THERAPIES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 224 UNITED ARAB EMIRATES: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY SOURCE, 2022–2029 (USD MILLION)
TABLE 225 UNITED ARAB EMIRATES: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY INDICATION, 2022–2029 (USD MILLION)
TABLE 226 UNITED ARAB EMIRATES: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY END USER, 2022–2029 (USD MILLION)
10.6.2.3 Other GCC Countries
TABLE 227 OTHER GCC COUNTRIES: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 228 OTHER GCC COUNTRIES: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR AUTOLOGOUS NON-STEM CELL THERAPIES, BY TYPE, 2022–2029 (USD MILLION)
TABLE 229 OTHER GCC COUNTRIES: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY SOURCE, 2022–2029 (USD MILLION)
TABLE 230 OTHER GCC COUNTRIES: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY INDICATION, 2022–2029 (USD MILLION)
TABLE 231 OTHER GCC COUNTRIES: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY END USER, 2022–2029 (USD MILLION)
10.6.2.4 Rest of the Middle East
TABLE 232 REST OF MIDDLE EAST: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 233 REST OF MIDDLE EAST: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR AUTOLOGOUS NON-STEM CELL THERAPIES, BY TYPE, 2022–2029 (USD MILLION)
TABLE 234 REST OF MIDDLE EAST: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY SOURCE, 2022–2029 (USD MILLION)
TABLE 235 REST OF MIDDLE EAST: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY INDICATION, 2022–2029 (USD MILLION)
TABLE 236 REST OF MIDDLE EAST: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY END USER, 2022–2029 (USD MILLION)
10.7 AFRICA
10.7.1 IMPROVEMENTS IN HEALTHCARE INFRASTRUCTURE TO SUPPORT MARKET GROWTH
TABLE 237 AFRICA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 238 AFRICA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR AUTOLOGOUS NON-STEM CELL THERAPIES, BY TYPE, 2022–2029 (USD MILLION)
TABLE 239 AFRICA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY SOURCE, 2022–2029 (USD MILLION)
TABLE 240 AFRICA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY INDICATION, 2022–2029 (USD MILLION)
TABLE 241 AFRICA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY END USER, 2022–2029 (USD MILLION)
10.7.2 AFRICA: RECESSION IMPACT
11 COMPETITIVE LANDSCAPE
11.1 OVERVIEW
11.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
FIGURE 33 STRATEGIES ADOPTED BY KEY PLAYERS
11.3 REVENUE ANALYSIS
FIGURE 34 REVENUE ANALYSIS OF KEY PLAYERS, 2021?2023
11.4 MARKET SHARE ANALYSIS
FIGURE 35 AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES: MARKET SHARE ANALYSIS, 2023 (TOP 3 PLAYERS)
TABLE 242 AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET: DEGREE OF COMPETITION
11.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
11.5.1 STARS
11.5.2 EMERGING LEADERS
11.5.3 PERVASIVE PLAYERS
11.5.4 PARTICIPANTS
FIGURE 36 AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2023
11.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023
11.5.5.1 Company footprint
FIGURE 37 AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET: COMPANY FOOTPRINT
11.5.5.2 Region footprint
TABLE 243 AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET: REGION FOOTPRINT
11.5.5.3 Type footprint
TABLE 244 AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET: TYPE FOOTPRINT
11.5.5.4 Source footprint
TABLE 245 AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET: SOURCE FOOTPRINT
11.5.5.5 Indication footprint
TABLE 246 AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET: INDICATION FOOTPRINT
11.6 COMPANY EVALUATION MATRIX: START-UPS/SMES, 2023
11.6.1 PROGRESSIVE COMPANIES
11.6.2 RESPONSIVE COMPANIES
11.6.3 DYNAMIC COMPANIES
11.6.4 STARTING BLOCKS
FIGURE 38 AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET: COMPANY EVALUATION MATRIX (START-UPS/SMES), 2023
11.6.5 COMPETITIVE BENCHMARKING: START-UPS/SMES, 2023
TABLE 247 AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET: DETAILED LIST OF KEY START-UPS/SMES
FIGURE 39 AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET: OVERALL FOOTPRINT FOR START-UPS/SMES
TABLE 248 AUTOLOGOUS STEM-CELL & NON-STEM CELL THERAPY MARKET: COMPETITIVE BENCHMARKING OF START-UPS/SMES
11.7 COMPANY VALUATION & FINANCIAL METRICS
FIGURE 40 EV/EBITDA OF KEY VENDORS
FIGURE 41 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS
11.8 BRAND/PRODUCT COMPARISON
TABLE 249 BRAND/PRODUCT COMPARISON FOR AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES (APPROVED THERAPIES)
11.8.1 GILEAD SCIENCES, INC.
11.8.2 BRISTOL-MYERS SQUIBB COMPANY
11.8.3 NOVARTIS AG
11.9 COMPETITIVE SCENARIO
11.9.1 PRODUCT LAUNCHES & APPROVALS
TABLE 250 AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021–MAY 2024
11.9.2 DEALS
TABLE 251 AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET: DEALS, JANUARY 2021–MAY 2024
TABLE 252 AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET: EXPANSIONS, JANUARY 2021–MAY 2024
11.9.3 OTHER DEVELOPMENTS
TABLE 253 AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPY MARKET: OTHER DEVELOPMENTS, JANUARY 2021–MAY 2024
12 COMPANY PROFILES
12.1 KEY PLAYERS
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
12.1.1 BRISTOL-MYERS SQUIBB COMPANY
TABLE 254 BRISTOL-MYERS SQUIBB COMPANY: COMPANY OVERVIEW
FIGURE 42 BRISTOL-MYERS SQUIBB COMPANY: COMPANY SNAPSHOT (2023)
TABLE 255 BRISTOL-MYERS SQUIBB COMPANY: PRODUCTS OFFERED
TABLE 256 BRISTOL-MYERS SQUIBB COMPANY: PRODUCT APPROVALS, JANUARY 2021?MAY 2024
TABLE 257 BRISTOL-MYERS SQUIBB COMPANY: DEALS, JANUARY 2021? MAY 2024
12.1.2 GILEAD SCIENCES, INC.
TABLE 258 GILEAD SCIENCES, INC.: COMPANY OVERVIEW
FIGURE 43 GILEAD SCIENCES, INC.: COMPANY SNAPSHOT (2023)
TABLE 259 GILEAD SCIENCES, INC.: PRODUCTS OFFERED
TABLE 260 GILEAD SCIENCES, INC.: PRODUCT APPROVALS, JANUARY 2021?MAY 2024
TABLE 261 GILEAD SCIENCES, INC.: DEALS, JANUARY 2021?MAY 2024
TABLE 262 GILEAD SCIENCES, INC.: OTHER DEVELOPMENTS, JANUARY 2021–MAY 2024
12.1.3 NOVARTIS AG
TABLE 263 NOVARTIS AG: COMPANY OVERVIEW
FIGURE 44 NOVARTIS AG: COMPANY SNAPSHOT
TABLE 264 NOVARTIS AG: PRODUCTS OFFERED
TABLE 265 NOVARTIS AG: PRODUCT LAUNCHES & APPROVALS,
JANUARY 2021?MAY 2024
TABLE 266 NOVARTIS AG: EXPANSIONS, JANUARY 2021?MAY 2024
TABLE 267 NOVARTIS AG: OTHER DEVELOPMENTS, JANUARY 2021?MAY 2024
12.1.4 JOHNSON & JOHNSON
TABLE 268 JOHNSON & JOHNSON: COMPANY OVERVIEW
FIGURE 45 JOHNSON & JOHNSON: COMPANY SNAPSHOT (2023)
TABLE 269 JOHNSON & JOHNSON: PRODUCTS OFFERED
TABLE 270 JOHNSON & JOHNSON: PRODUCT APPROVALS, JANUARY 2021?MAY 2024
TABLE 271 JOHNSON & JOHNSON: DEALS, JANUARY 2021?MAY 2024
12.1.5 VERICEL CORPORATION
TABLE 272 VERICEL CORPORATION: COMPANY OVERVIEW
FIGURE 46 VERICEL CORPORATION: COMPANY SNAPSHOT (2023)
TABLE 273 VERICEL CORPORATION: PRODUCTS OFFERED
TABLE 274 VERICEL CORPORATION: EXPANSIONS, JANUARY 2021?MAY 2024
12.1.6 IOVANCE BIOTHERAPEUTICS, INC.
TABLE 275 IOVANCE BIOTHERAPEUTICS, INC.: COMPANY OVERVIEW
FIGURE 47 IOVANCE BIOTHERAPEUTICS, INC.: COMPANY SNAPSHOT (2023)
TABLE 276 IOVANCE BIOTHERAPEUTICS, INC.: PRODUCTS OFFERED
TABLE 277 IOVANCE BIOTHERAPEUTICS, INC.: PRODUCT APPROVALS, JANUARY 2021?MAY 2024
TABLE 278 IOVANCE BIOTHERAPEUTICS, INC.: EXPANSIONS, JANUARY 2021?MAY 2024
12.1.7 JW (CAYMAN) THERAPEUTICS CO. LTD
TABLE 279 JW (CAYMAN) THERAPEUTICS CO. LTD: COMPANY OVERVIEW
FIGURE 48 JW (CAYMAN) THERAPEUTICS CO. LTD: COMPANY SNAPSHOT (2023)
TABLE 280 JW (CAYMAN) THERAPEUTICS CO. LTD: PRODUCTS OFFERED
TABLE 281 JW (CAYMAN) THERAPEUTICS CO. LTD: PRODUCT APPROVALS, JANUARY 2021?MAY 2024
TABLE 282 JW (CAYMAN) THERAPEUTICS CO. LTD: DEALS
12.1.8 PHARMICELL CO., LTD.
TABLE 283 PHARMICELL CO., LTD.: COMPANY OVERVIEW
TABLE 284 PHARMICELL CO., LTD: PRODUCTS OFFERED
12.1.9 HOLOSTEM S.R.L.
TABLE 285 HOLOSTEM S.R.L.: COMPANY OVERVIEW
TABLE 286 HOLOSTEM SRL: PRODUCTS OFFERED
12.1.10 HEALIVA SA
TABLE 287 HEALIVA SA: COMPANY OVERVIEW
TABLE 288 HEALIVA SA: PRODUCTS OFFERED
TABLE 289 HEALIVA SA: DEALS
12.1.11 APAC BIOTECH
TABLE 290 APAC BIOTECH: COMPANY OVERVIEW
TABLE 291 APAC BIOTECH: PRODUCTS OFFERED
12.1.12 IMMUNOADOPTIVE CELL THERAPY PRIVATE LIMITED (IMMUNOACT)
TABLE 292 IMMUNOADOPTIVE CELL THERAPY PRIVATE LIMITED: COMPANY OVERVIEW
TABLE 293 IMMUNOADOPTIVE CELL THERAPY PRIVATE LIMITED: PRODUCTS OFFERED
TABLE 294 IMMUNOADOPTIVE CELL THERAPY PRIVATE LIMITED: DEALS
TABLE 295 IMMUNOADOPTIVE CELL THERAPY PRIVATE LIMITED: OTHER DEVELOPMENTS, JANUARY 2021–MAY 2024
12.1.13 REGROW BIOSCIENCES PVT LTD.
TABLE 296 REGROW BIOSCIENCES PVT LTD.: COMPANY OVERVIEW
TABLE 297 REGROW BIOSCIENCES PVT LTD.: PRODUCTS OFFERED
TABLE 298 REGROW BIOSCIENCES PVT LTD.: PRODUCT APPROVALS, JANUARY 2021?MAY 2024
12.1.14 TEGO SCIENCE, INC.
TABLE 299 TEGO SCIENCE, INC.: COMPANY OVERVIEW
TABLE 300 TEGO SCIENCE, INC.: PRODUCTS OFFERED
12.1.15 CARSGEN THERAPEUTICS HOLDINGS LIMITED
TABLE 301 CARSGEN THERAPEUTICS HOLDINGS LIMITED: COMPANY OVERVIEW
TABLE 302 CARSGEN THERAPEUTICS HOLDINGS LIMITED: PRODUCTS OFFERED
TABLE 303 CARSGEN THERAPEUTICS HOLDINGS LIMITED: PRODUCT APPROVALS, JANUARY 2021?MAY 2024
TABLE 304 CARSGEN THERAPEUTICS HOLDINGS LIMITED: EXPANSIONS
TABLE 305 CARSGEN THERAPEUTICS HOLDINGS LIMITED: DEALS
12.1.16 IASO BIOTHERAPEUTICS
TABLE 306 IASO BIOTHERAPEUTICS: COMPANY OVERVIEW
TABLE 307 IASO BIOTHERAPEUTICS: PRODUCTS OFFERED
TABLE 308 IASO BIOTHERAPEUTICS: PRODUCT APPROVALS
TABLE 309 IASO BIOTHERAPEUTICS: DEALS
12.1.17 ANTEROGEN.CO.,LTD.
TABLE 310 ANTEROGEN.CO.,LTD.: COMPANY OVERVIEW
TABLE 311 ANTEROGEN.CO.,LTD.: PRODUCTS OFFERED
12.1.18 GREEN CROSS HOLDINGS CO., LTD. (GC CELL)
TABLE 312 GREEN CROSS HOLDINGS CO., LTD. (GC CELL): COMPANY OVERVIEW
FIGURE 49 GREEN CROSS HOLDINGS CO., LTD. (GC CELL): COMPANY OVERVIEW (2023)
TABLE 313 GREEN CROSS HOLDINGS CO., LTD. (GC CELL): PRODUCTS OFFERED
TABLE 314 GREEN CROSS HOLDINGS CO., LTD. (GC CELL): DEALS
12.1.19 SANPOWER GROUP CO., LTD. (DENDREON PHARMACEUTICALS LLC.)
TABLE 315 SANPOWER GROUP CO., LTD.: COMPANY OVERVIEW
TABLE 316 SANPOWER GROUP CO., LTD. (DENDREON): PRODUCTS OFFERED
12.2 OTHER PLAYERS
12.2.1 PROKIDNEY CORP.
TABLE 317 PROKIDNEY CORP.: COMPANY OVERVIEW
12.2.2 BIOCARDIA, INC.
TABLE 318 BIOCARDIA, INC.: COMPANY OVERVIEW
12.2.3 NEUROPLAST B.V.
TABLE 319 NEUROPLAST B.V.: COMPANY OVERVIEW
12.2.4 ADAPTIMMUNE THERAPEUTICS PLC
TABLE 320 ADAPTIMMUNE THERAPEUTICS PLC.: COMPANY OVERVIEW
12.2.5 AGONOX, INC.
TABLE 321 AGONIX, INC.: COMPANY OVERVIEW
12.2.6 KYVERNA THERAPEUTICS, INC.
TABLE 322 KYVERNA THERAPEUTICS, INC.: COMPANY OVERVIEW
12.2.7 OBSIDIAN THERAPEUTICS, INC.
TABLE 323 OBSIDIAN THERAPEUTICS, INC.: COMPANY OVERVIEW
12.2.8 AVOTRES INC.
TABLE 324 AVOTRES, INC.: COMPANY OVERVIEW
12.2.9 CORESTEMCHEMON INC.
TABLE 325 CORESTEMCHEMON INC.: COMPANY OVERVIEW
12.2.10 JUVENTAS CELL THERAPY LTD.
TABLE 326 JUVENTAS CELL THERAPY LTD.: COMPANY OVERVIEW
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.
13 APPENDIX
13.1 DISCUSSION GUIDE
13.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
13.3 CUSTOMIZATION OPTIONS
13.4 RELATED REPORTS
13.5 AUTHOR DETAILS
